29 May 2025NewsAmericasRavi Srinivasan, JA Kemp

WATCH: Evergreening (or life cycle management patents—including polymorphs and patents arising from clinical trial data

Ravi Srinivasan of JA Kemp explores strategies for identifying, prosecuting, and defending follow-on patent applications after a therapeutic product enters the public domain. The session at LSPN covers patents based on clinical trial data and polymorphs of small molecule drugs.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
16 April 2026   The Cambridge biotech is accused of infringing six patents covering technologies used to target drug-resistant cancer mutations.
Americas
14 April 2026   A US district court has allowed key elements of the generic drugmaker’s case against a rival to move forward, while drawing clear limits on how far the complaint can reach.
Americas
13 April 2026   The US tech company targets a disgruntled ex-employee for threatening to sell its trade secrets if he does not receive an “unreasonable fee”.